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Antiretroviral therapyThe human immunodeﬁciency virus replication cycle begins by sequential interactions between viral
envelope glycoproteins with CD4 molecule and a member of the seven-transmembrane, G-protein-coupled,
receptors' family (coreceptor).
In this report we focused on the contribution of CCR8 as alternative coreceptor for HIV-1 and HIV-2 isolates.
We found that this coreceptor was efﬁciently used not only by HIV-2 but particularly by HIV-1 isolates. We
demonstrate that CXCR4 usage, either alone or together with CCR5 and/or CCR8, was more frequently
observed in HIV-1 than in HIV-2 isolates. Directly related to this is the ﬁnding that the non-usage of CXCR4 is
signiﬁcantly more common in HIV-2 isolates; both features could be associated with the slower disease
progression generally observed in HIV-2 infected patients.
The ability of some viral isolates to use alternative coreceptors besides CCR5 and CXCR4 could further impact
on the efﬁcacy of entry inhibitor therapy and possibly also in HIV pathogenesis.ular, Unidade dos Retrovirus e
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The human immunodeﬁciency virus (HIV) replication cycle begins
by sequential interactions between viral envelope glycoproteins and
cellular receptors that ultimately lead to viral envelope and cell
membrane fusion. The cellular receptors involved in these initial
events are the CD4 molecule (Dalgleish et al., 1984; Klatzmann et al.,
1984) and a member of seven-transmembrane, G-protein-coupled,
receptors' (GPCRs) family, referred as coreceptor. At the present,
twenty three of these GPCRs have been shown to act in vitro as
coreceptors for human immunodeﬁciency viruses 1 and 2 (HIV-1 and
HIV-2, respectively) and simian immunodeﬁciency virus (SIV): CCR1,CCR2b, CCR3, CCR4, CCR5, CCR8, CCR9, CCR10, CXCR2, CXCR4, CXCR5,
CXCR6, CX3CR1, XCR1, FPRL1, GPR1, GPR15, APJ, ChemR23, CXCR7/
RDC1, D6, BLTR and US28 (Broder and Jones-Trower, 1999; Neil et al.,
2005; Shimizu et al., 2009; Simmons et al., 2000). Despite this array of
potential coreceptors, only CCR5 and CXCR4 have been considered as
major coreceptors and apparently the only that are relevant in HIV
pathogenesis (Simmons et al., 2000; Y.J. Zhang et al., 1998). In fact,
several reports corroborate the idea that CCR5 is important in HIV-1
transmission (Dean et al., 1996; Liu et al., 1996; Mummidi et al., 1998;
Samson et al., 1996a). CCR5-using (R5) variants are also predominant
during early stages of HIV-1 infection and only in approximately 40%
of infected humans, viruses arise that can use CXCR4 in addition to
(R5X4 strains), or sometimes instead of CCR5 (X4 strains) (Berger
et al., 1998, 1999; Simmons et al., 1996). The emergence of such
strains is associated with accelerated CD4+ T-cell loss and disease
progression (Bjorndal et al., 1997; Connor and Ho, 1994; Connor et al.,
1997; Richman and Bozzette, 1994).
Themajority of the information regarding coreceptor usage by HIV
strains derives almost exclusively from studies using HIV-1 isolates.
However, we and others (Azevedo-Pereira et al., 2003; Bron et al.,
1997; Guillon et al., 1998; McKnight et al., 1998; Reeves et al., 1999;
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HIV-2 interaction with cellular receptors is remarkably different. HIV-
2 isolates that are able to infect cells in the absence of CD4, the
promiscuous use of chemokine receptors as coreceptors and the non-
usage of either CCR5 or CXCR4 are notorious examples of the
heterogeneous mechanisms bywhich HIV-2 interacts with and infects
target cells.
CCR8 is a chemokine receptor that is expressed in different cell
types including monocytes and T-lymphocytes (Goya et al., 1998;
Roos et al., 1997; Samson et al., 1996b; Tiffany et al., 1997) and is
preferentially detected on type 2 T-helper lymphocyte subpopulation
(D'Ambrosio et al., 1998; Zingoni et al., 1998). There are also reports
suggesting that CCR8 is also expressed by NK cells (Inngjerdingen
et al., 2000), and nonhematopoietic cells such as endothelial cells
(Haque et al., 2001), smooth muscle cells (Haque et al., 2004), and
certain brain-derived cells (Jinno et al., 1998).
Furthermore, CCR8 has been described as a possible coreceptor for
some HIV and SIV strains (Cilliers et al., 2005; Horuk et al., 1998;
Isaacman-Beck et al., 2009; Lee et al., 2000; Liu et al., 2000; Ohagen et
al., 2003; Rucker et al., 1997; Shimizu et al., 2009; Singh et al., 1999;
Vodros et al., 2003; Willey et al., 2003). Due to its expression pattern,
particularly in activated peripheral blood lymphocytes, monocytes
and thymocytes, CCR8 could potentially have a role in HIV infection
and pathogenesis and it may serve as a relevant HIV coreceptor in vivo.
In this report we analysed CCR5 and CXCR4 coreceptor usage by
diverse HIV-2 and HIV-1. In addition to these two major coreceptors,
we focused on the contribution of CCR8 as an alternative coreceptor in
HIV-2 infection, using primary isolates obtained from patients at
different disease stages, including sequential samples from speciﬁc
patients. Additionally, we also address the capability of CCR8 to
function as coreceptor for selected HIV-1 isolates. Our main objective
was to understand to what extent CCR8 could be considered as a
reliable alternative coreceptor for HIV-1 and HIV-2 primary isolates.
We found that 26.2% (17/65) of the HIV-2 isolates tested are able to
use this chemokine receptor to enter target cells regardless of the
patient's clinical status, viral load or CD4+ T-cell counts. Furthermore,
56.7% (17/30) of the HIV-1 isolates are able to use CCR8 as coreceptor.
We conclude that CCR8 could constitute a potential alternative
coreceptor not only for HIV-2 but also for HIV-1 infection, a fact that
may have implications for current therapeutic strategies that aim to
block viral entry.
Results
Patient's clinical and immunologic data
The overall characteristics of the clinical, immunological and
plasma viral load data of the patients from which the viruses were
isolated are summarized in Table 1 and in more detail in Tables 2 and
3. The majority (72.3%; 47/65) of HIV-2 infected patients included in
this cohort were symptomatic when blood sample was collected
(Table 1). According to CDC classiﬁcation system (CDC, 1992),
symptomatic stage was deﬁned as belonging to clinical categories B
or C. The CD4 cell counts ranged from 50 to 964, with an average valueTable 1
Patient's clinical, immunological and virological characteristics of the HIV-1 and HIV-2 coho
Clinical stagea CD4 cell cou
% (n) % (n)
Cohort (n) Asymptomatic Symptomatic ≤200
HIV-1 (30) 26.7 (8) 73.3 (22) 20.0 (6)
HIV-2 (65) 27.7 (18) 72.3 (47) 32.3 (21)
a Clinical stage according to CDC classiﬁcation (CDC, 1992); Asymptomatic = clinical sta
b Number of T-CD4 lymphocytes/μl.
c Copies of viral RNA/ml.of 338 T-CD4+ lymphocytes/μl of peripheral blood; 32.3% (21/65) of
the patients had CD4+ cell counts below 200 and 58.5% (38/65) have
levels of plasma viral load below 500 viral RNA copies/ml.
In the HIV-1 cohort (Table 1), 73.3% (22/30) of the patients were
symptomatic; the CD4-cell counts range was 106–1455 (average:
455). The CD4 cell count was below 200 in 20% (6/30) and plasma
viral load below 500 copies of viral RNA/ml was observed also in 20%
(6/30) of the individuals included in the study.
CCR5, CXCR4 and CCR8 coreceptor usage by HIV-2 primary isolates
Although HIV-2 primary isolates with broad coreceptor usage have
been described, the frequencies with which these different corecep-
tors are used have not been conclusively determined, mainly because
the majority of data available was obtained from studies based on
small cohorts. In this study we analysed a total of 65 primary HIV-2
isolates, obtained from patients at different clinical stages and with
different CD4+ T-cell counts and plasma viral load levels. We wanted
to verify their capability to infect GHOST–CD4 cells individually
expressing CCR5, CXCR4 and CCR8 coreceptors. The ability to use
these coreceptors was analysed by the capacity to productively infect
GHOST coreceptor-expressing cells, measuring viral progeny produc-
tion by RT activity and scored as semi-quantitative results. The
biotype of each isolate was assigned according to coreceptor usage
proﬁle (Table 2).
The results show that 62 out of 65 HIV-2 isolates are able to use
CCR5 (95.4%), and CXCR4 mediated infection of 31 out of 65 strains
(47.7%). Moreover, seventeen HIV-2 isolates are able to use CCR8 as
coreceptor (26.2%). No replication was observed in GHOST–CD4
parental cell line (data not shown).
The effective usage of CCR8was further conﬁrmed in both GHOST–
CD4–CCR8 and in peripheral blood mononuclear cells (PBMC) using
blocking concentrations of I-309 (in GHOST–CD4–CCR8 cell line) or I-
309 together with TAK-779 and AMD3100 (in PBMC). We selected a
group of isolates (both HIV-1 and HIV-2) that showed a biotype
characterized by high replication levels in CCR8 expressing cells
(UCFL2018, UCFL2051, UCFL1007 and UCFL1016). As controls, we also
included an R5 and anX4 isolate (ALI andUCFL2049, respectively). The
results, summarized in Fig. 1, demonstrate that the replication of all
the isolates inGHOST–CD4–CCR8 cell linewas completely abrogated in
the presence of 100 ng/ml of I-309 (Fig. 1A), conﬁrming that CCR8was
the only coreceptor being used in that cell system. In PBMC, we used a
combination of CCR5 and CXCR4-targeted inhibitors (TAK-779 and
AMD3100, respectively) in the presence or absence of CCR8 ligand, I-
309. In these experiments we used CD8-depleted PBMC in order to
avoid any uncontrolled inhibition exertedby soluble factors eventually
secreted by CD8+ T-cells. The results (Fig. 1B) reveal that I-309
inhibited the replication of these isolates in PBMC (Pb0.001),
indicating that CCR8 was efﬁciently used in this cell system.
Nevertheless, none of the HIV isolates tested was fully inhibited,
even when combining I-309 with TAK-779 and AMD3100. This was
particularly evident with UCFL2018 and UCFL1007 isolates, suggest-
ing that these isolates could be using an additional coreceptor, besides
CCR8, CCR5 and CXCR4, expressed in PBMCs.rts included in the study.
ntsb Plasma viral loadc
% (n)
N200 ≥500 b500 ND
80.0 (24) 76.7 (23) 20.0 (6) 3.3 (1)
67.7 (44) 26.1 (17) 58.5 (38) 15.4 (10)
ge A; Symptomatic = clinical stage B or C.
Table 2
CCR5, CXCR4 and CCR8 coreceptor usage by HIV-2 isolates and patient's clinical, immunological and virological data.
Isolate Clinical stagea CD4 cell countb Plasma viral loadc Coreceptors usedd Biotype
CCR5 CXCR4 CCR8
ALI Symptomatic 491 ND +++ − − R5
UCFL2001 Symptomatic 230 b500 +++ − − R5
UCFL2003 Symptomatic 145 2373 + +++ +++ R5X4R8
UCFL2004 Symptomatic 442 1418 + + − R5X4
UCFL2005 Symptomatic 365 b500 + + + R5X4R8
UCFL2006 Asymptomatic 562 b500 + + + R5X4R8
UCFL2007 Asymptomatic 331 b500 + − + R5R8
UCFL2008 Symptomatic 52 2285 +++ +++ +++ R5X4R8
UCFL2009 Symptomatic 527 b500 + + − R5X4
UCFL2010 Asymptomatic 456 b500 ++ − − R5
UCFL2012 Symptomatic 375 1268 +++ − − R5
UCFL2013 Symptomatic 500 816 + − − R5
UCFL2014 Symptomatic 213 b500 ++ − − R5
UCFL2015 Symptomatic 220 b500 + + − R5X4
UCFL2016 Symptomatic 213 b500 + − − R5
UCFL2017 Symptomatic 50 23,454 ++ ++ ++ R5X4R8
UCFL2018 Symptomatic 392 b500 +++ ++ +++ R5X4R8
UCFL2019 Symptomatic 258 1870 ++ − − R5
UCFL2020 Symptomatic 358 b500 + + − R5X4
UCFL2022 Symptomatic 578 b500 + + − R5X4
UCFL2023 Symptomatic 70 b500 ++ − − R5
UCFL2024 Asymptomatic 683 b500 + − − R5
UCFL2026 Asymptomatic 921 b500 +++ − − R5
UCFL2027 Asymptomatic 730 b500 ++ − − R5
UCFL2028 Asymptomatic 760 b500 +++ − − R5
UCFL2029 Symptomatic 230 3454 + + + R5X4R8
UCFL2030 Symptomatic 346 b500 ++ − − R5
UCFL2031 Symptomatic 92 b500 +++ − − R5
UCFL2032 Symptomatic 106 1072 − + − X4
UCFL2033 Symptomatic 139 N100,000 ++ − − R5
UCFL2034 Asymptomatic 432 9470 ++ − − R5
UCFL2035 Symptomatic 292 6431 +++ ++ − R5X4
UCFL2036 Symptomatic 195 b500 +++ − − R5
UCFL2037 Symptomatic 419 b500 +++ − + R5R8
UCFL2038 Symptomatic 318 b500 +++ − − R5
UCFL2039 Symptomatic 384 b500 + + − R5X4
UCFL2040 Symptomatic 91 b500 + − − R5
UCFL2041 Symptomatic 184 b500 ++ − − R5
UCFL2042 Asymptomatic 413 b500 + + − R5X4
UCFL2043 Symptomatic 324 b500 + − + R5R8
UCFL2045 Asymptomatic 267 1947 +++ − − R5
UCFL2046 Asymptomatic 130 b500 +++ − − R5
UCFL2048 Symptomatic 59 1698 + − ++ R5R8
UCFL2049 Symptomatic 84 b500 − + − X4
UCFL2050 Asymptomatic 697 b500 +++ − − R5
UCFL2051 Asymptomatic 605 b500 +++ ++ +++ R5X4R8
UCFL2053 Symptomatic 259 b500 +++ − − R5
UCFL2054 Asymptomatic 801 b500 + + − R5X4
UCFL2055 Symptomatic 127 13,883 + + + R5X4R8
UCFL2056 Symptomatic 230 831 + + + R5X4R8
UCFL2057 Symptomatic 219 b500 +++ − − R5
UCFL2058 Symptomatic 224 b500 ++ − − R5
UCFL2059 Asymptomatic 197 b500 +++ +++ − R5X4
UCFL2060 Asymptomatic 896 ND +++ +++ − R5X4
UCFL2061 Asymptomatic 964 ND +++ + − R5X4
UCFL2062 Asymptomatic 554 b500 + − − R5
UCFL2063 Symptomatic 304 b500 + − − R5
UCFL2064 Symptomatic 144 N100,000 + ++ − R5X4
UCFL2065 Symptomatic 263 ND + + + R5X4R8
UCFL2066 Symptomatic 126 ND + + − R5X4
UCFL2067 Symptomatic 186 ND +++ + +++ R5X4R8
UCFL2068 Symptomatic 96 ND − + − X4
UCFL2069 Symptomatic 485 ND + − − R5
UCFL2070 Symptomatic 108 ND +++ ++ − R5X4
UCFL2071 Symptomatic 74 ND + + + R5X4R8
a Clinical stage according to CDC classiﬁcation (CDC, 1992); Asymptomatic=clinical stage A; Symptomatic=clinical stage B or C.
b Number of T-CD4 lymphocytes/μl.
c Copies of viral RNA/ml; ND, not determined.
d Peak RT activity measured in culture supernatants during a 21 day-period after virus inoculation.− peak RT activity b10 pg/ml; + peak RT activity between 10 and 100 pg/ml;
++ peak RT activity between 101 and 1000 pg/ml; +++ peak RT activity N1000 pg/ml.
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Table 3
















UCFL2013 S 500 816 + − −
UCFL2014 52 S 213 b500 ++ − −
UCFL2015 41 S 220 b500 + + −
Patient
#2
UCFL2018 S 392 b500 +++ ++ +++
UCFL2019 90 S 258 1870 ++ − −
Patient
#3
UCFL2027 A 730 b500 ++ − −
UCFL2028 61 A 760 b500 +++ − −
Patient
#4
UCFL2030 S 346 b500 ++ − −
UCFL2031 246 S 92 b500 ++ − −
Patient
#5
UCFL2034 A 432 9470 ++ − −
UCFL2035 57 S 292 6431 +++ ++ −
UCFL2036 30 S 195 b500 +++ − −
Patient
#6
UCFL2037 S 419 b500 +++ − +
UCFL2038 73 S 318 b500 +++ − −
Patient
#7
UCFL2045 A 267 1947 +++ − −
UCFL2046 79 A 130 b500 +++ − −
Patient
#8
UCFL2048 S 59 1698 + − ++
UCFL2049 32 S 84 b500 − + −
Patient
#9
UCFL2050 A 697 b500 +++ − −
UCFL2051 78 A 605 b500 +++ ++ +++
a Elapsed time after previous blood withdrawal in sequential samples from the same
patient.
b Clinical stage according to CDC classiﬁcation (CDC, 1992); A, Asymptomatic =
clinical stage A; S, Symptomatic = clinical stage B or C.
c Number of T-CD4 lymphocytes/μl.
d Copies of viral RNA/ml; ND, not determined.
e Peak RT activity measured in culture supernatants during a 21 day-period after
virus inoculation. − peak RT activity b10 pg/ml; + peak RT activity between 10 and
100 pg/ml; ++ peak RT activity between 101 and 1000 pg/ml; +++ peak RT activity
N1000 pg/ml.
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of this cohort, we analysed the correlation between HIV-2 coreceptor
usage, patient's clinical stage and CD4+ T-cell counts. We aim to
address two central questions: whether or not CCR5 usage is observed
mainly in individuals with higher CD4+ T-cell counts and lower viral
load; and whether the acquisition of CXCR4 usage could be related
with more severe immunodeﬁciency (deﬁned by CD4+ T-cell counts
below 200 cells/μl) and with increased levels of plasma virémia
(above 500 RNA copies/ml). The statistical analysis of the data
presented in Table 2 indicates that differential usage of CCR5,
CXCR4 or CCR8 by HIV-2 is not correlated (PN0.05) with the clinical
stage or with the immunological/virological data of the infected
patients. The values of P obtained were: P=0.522 (CD4 T-cell counts
vs. CCR5 usage), P=0.149 (CD4 T-cell counts vs. CXCR4 usage),
P=0.289 (CD4 T-cell counts vs. CCR8 usage), P=0.912 (viral load vs.
CCR5 usage), P=0.056 (viral load vs. CXCR4 usage) and P=0.057
(viral load vs. CCR8 usage).
From our results is remarkable that only three out of 65 HIV-2
tested (4.6%) show an X4 phenotype (exclusive CXCR4 usage), in
contrast to 46.2% (30/65) of strains that only use the CCR5 coreceptor
(R5 phenotype). This is particularly noteworthy considering that 47
out of 65 (72.3%) of the HIV-2 viruses tested were obtained from
symptomatic patients (Tables 1 and 2). Furthermore, the R5
phenotype was observed regardless of patient's CD4 cell count and/
or plasma viral load.
Coreceptor usage by HIV-2 primary isolates obtained from sequential
samples
To further address the critical question about the evolutionary
dynamics of coreceptor usage during disease progression, and
whether X4 variants arise as a consequence of immune depletion,
we analysed the evolution of coreceptor usage within several infectedindividuals from which follow-up blood samples could be obtained. A
total of twenty sequential viruses isolated from nine different patients
were studied, including four that were asymptomatic at the beginning
of the follow-up. The elapsed time between consecutive samples
ranged from thirty to 246 weeks (average: 76 weeks). The results
(Table 3) reveal that only one patient had evolved from asymptomatic
to symptomatic clinical stage (patient #5). A decrease in CD4+ T-cell
counts was observed in six out of nine patients. All the initial isolates
obtained from the earliest samples were R5 except those from
patients #2 (R5X4R8) and #6 (R5R8). Interestingly, both isolates lost
the ability to use CXCR4 and/or CCR8 coreceptors in sequential viruses
obtained ninety and 73 weeks later, respectively.
Although the number of samples was too small to get a consistent
analysis we may conclude that in this follow-up cohort there is no
correlation between a decrease in CD4+ cell count and the acquisition
of CXCR4 or CCR8 usage (PN0.05). Despite this disagreement between
viral biotype and immunological status, it is noteworthy the
evolutionary dynamics of viral biotype observed within isolates
obtained from patient #5 (UCFL2034, UCFL2035 and UCFL2036).
This patient was the only that showed a clinical evolution during the
follow-up period from asymptomatic to symptomatic and viral
biotype changed from R5 (UCFL2034) to R5X4 (UCFL2035), reverting
again to R5 (UCFL2036). This coreceptor evolution was concomitant
with a decrease in both plasma viral load and CD4+ T-cell counts.
Interestingly, after isolation of UCFL2035, this patient initiated anti-
retroviral therapy with a protease inhibitor and two nucleoside
analogue reverse transcriptase inhibitors.
Also remarkable was the evolution of viral biotype observed in
patients #2, #6 and #8. In all of them, CCR8 using variants appear to be
cleared from the predominant viral population in peripheral blood.
Although any assumption regarding the reasons underlying this
evolution needs to be further tested, this observation may suggest that
these variants could have intrinsic disadvantages, perhaps a lower viral
ﬁtness or an increased susceptibility to host immunological response.
CCR5, CXCR4 and CCR8 coreceptor usage by HIV-1 primary isolates
In HIV-1 infection, the emergence of variants able to use other
coreceptors besides CCR5 and CXCR4 has been referred occasionally
and much less frequently than in HIV-2. In order to compare the
pattern of coreceptor usage proﬁle observed in the HIV-2 cohort we
also investigate the contribution of CCR5, CXCR4 and CCR8 as
coreceptors for diverse HIV-1 isolates. We are particularly interested
in ascertaining the frequency with which CCR8 was used as viral
coreceptor. With this aim we analysed thirty primary HIV-1 isolates
obtained from patients at different clinical stages and with distinct
CD4+ T-cell counts (Tables 1 and 4). The results, summarized in
Table 4 and analysed according to the same criteria mentioned for
Table 2, reveal that, as in HIV-2 group, CCR5 and CXCR4 are the main
coreceptors used by HIV-1: 93.3% and 83.3% of the isolates were able
to infect productively CCR5 and CXCR4-expressing cells, respectively.
However, quite unexpectedly, but with statistical signiﬁcance, we
found that CCR8 could be used as coreceptor by seventeen out of
thirty isolates tested (56.7%), more frequently than in HIV-2 group
(26.2%; Pb0.001). As already noticed in HIV-2 isolates, the use of this
alternative coreceptor was observed regardless of the clinical stage,
the plasma viral load or the CD4+ T-cell counts. Regarding CXCR4
usage by HIV-1 and HIV-2, it is noteworthy that the ability to infect
CXCR4-expressing cells was more frequently observed in HIV-1
(83.3%) than in HIV-2 isolates (47.7%; Pb0.001).
Discussion
HIV infection in vitro could be mediated by a wide range of
different seven-transmembrane G-protein coupled chemokine recep-
tors. Despite the relative promiscuous usage of these coreceptors in
Fig. 1. Inhibition assay of CCR8-using HIV isolates. In these assays, HIV primary isolates were normalized by RT activity levels, and equivalent amounts of each isolate were added to
GHOST–CD4/CCR8 [panel (A)] or CD8-depleted PBMC [panel (B)] in the presence or absence of the different inhibitors used: I-309 [panel (A)] or I-309, TAK-779 and AMD3100 [panel
(B)], according to the tables. Data were analysed using GraphPad Prism software, version 4.0, and are representative of at least three independent assays. Data represent the mean of
residual replication (%)±standard error of the mean (bars). The biotype of each isolate is indicated according to coreceptor usage. (A) Inhibition assay of CCR8-using HIV isolates by
I-309 using GHOST–CD4/CCR8 cell line; the table below the X-axis indicates the presence (+) or absence (−) of I-309. A star indicates statistical signiﬁcant difference (Pb0.001)
between themedians of the percentage of residual replication in the absence and the presence of I-309. (B) Inhibition assay of CCR8-using HIV isolates by I-309 using PBMC; the table
below the X-axis indicates the presence (+) or absence (−) of TAK-779, AMD3100 and I-309. A star indicates statistical signiﬁcant difference (Pb0.001) between the medians of the
percentage of residual replication in the presence of AMD3100+TAK-779 alone and in the combination of AMD3100+TAK-779+I-309.
178 M. Calado et al. / Virology 408 (2010) 174–182vitro by certain HIV-1 and particularly HIV-2 strains (Broder and
Jones-Trower, 1999; Bron et al., 1997; Guillon et al., 1998; McKnight
et al., 1998; Morner et al., 1999; Owen et al., 1998), the majority of
recent studies concerning coreceptor usage by HIV isolates have been
focused in the two major chemokine receptors: CCR5 and CXCR4.
Accordingly, only limited information is available regarding CCR8
usage (or other minor coreceptors) by primary HIV-1 and HIV-2
isolates. The role of alternative coreceptors, besides CCR5 and CXCR4,
in HIV-1 infection is considered as being of limited importance in vitro
and probably in vivo (Moore et al., 2004; Y.J. Zhang et al., 1998);
accordingly, only CCR5 and CXCR4 are potential targets for therapeu-
tic intervention. However, some exceptions have been reported
(Cilliers et al., 2003, 2005; Deng et al., 1997; Edinger et al., 1998;
Lee et al., 2000; Pohlmann et al., 1999; Shimizu et al., 2009; Willey
et al., 2003; Xiao et al., 1998), revealing that some isolates can exploit
alternate coreceptors in vitro although whether such coreceptors are
used by HIV-1 in vivo remains unclear (Zhang and Moore, 1999).
Nevertheless, the possibility that alternative molecules could have
physiological relevance in vivo as a cofactor for HIV-1 infection
remains open. The same is true concerning HIV-2 infection, where the
more promiscuous usage of chemokine receptors as coreceptors has
been widely referred in vitro (Bron et al., 1997; Guillon et al., 1998;
McKnight et al., 1998). Additionally, the existence of primary isolates
with atypical coreceptor usage proﬁle (Azevedo-Pereira et al., 2003;
Sol et al., 1997; Zhang et al., 2000), may further indicate that in HIV-2
the capacity to use other coreceptors besides CCR5 and CXCR4 should
be potentially more common.In this report we analysed the role of CCR8 chemokine receptor as
coreceptor for HIV-1 and HIV-2 primary isolates. CCR8, formerly
knownas TER1, ChemR1 andCKR-L1, is the receptor for the chemokine
CCL1/I-309 (Roos et al., 1997; Tiffany et al., 1997). Additionally, three
virally encoded ligands are also known to interact with CCR8: vMIP-I
and vMIP-II (encoded by HHV-8) and vMCC-I encoded by Molluscum
contagiosum poxvirus (Dairaghi et al., 1999). The rationale underlying
the inclusion of CCR8 as an alternative coreceptormediatingHIV-2 and
HIV-1 infection, stems from the cellular and tissue distribution of this
chemokine receptor in vivo that includes somemajor cellular targets of
HIV infection. Namely, CCR8 expression has been detected on
monocytes, thymocytes and peripheral blood T-lymphocytes with
Th2 cytokine proﬁle (D'Ambrosio et al., 1998; Napolitano et al., 1996;
Tiffany et al., 1997; Zaballos et al., 1996; Zingoni et al., 1998).
CCR8 usage by certain HIV strains was referred in earlier reports
(Isaacman-Beck et al., 2009; Liu et al., 2000; Ohagen et al., 2003;
Rucker et al., 1997; Shimizu et al., 2009; Singh et al., 1999;Willey et al.,
2003). The majority of these reports used T-cell culture adapted
(TCLA) strains and the total number of strains tested ranged from
seven (Singh et al., 1999) to 22 (Rucker et al., 1997). In these studies,
the percentage of viruses able to use CCR8 was quite heterogeneous,
ranging from12.5% (Isaacman-Beck et al., 2009) to 81.8% (Willey et al.,
2003). Interestingly in this latter report, all the HIV-1 strains tested
(including primary isolates) proved to be able to infect NP2/CD4 cell
line expressing CCR8; someof themas efﬁciently as they infect CCR5 or
CXCR4 expressing cells (Willey et al., 2003). Furthermore, CCR8 usage
in primary cellswas demonstrated for twoHIV-1 isolates (Cilliers et al.,
Table 4
CCR5, CXCR4 and CCR8 coreceptor usage by HIV-1 isolates and patient's clinical,
immunological and virological data.








UCFL1001 Symptomatic 561 10,513 − + − X4
UCFL1002 Symptomatic 348 19,568 +++ +++ ++ R5X4R8
UCFL1003 Symptomatic 249 112,010 +++ ++ − R5X4
UCFL1005 Asymptomatic 1003 b500 + + − R5X4
UCFL1004 Asymptomatic 1125 b500 +++ ++ − R5X4
UCFL1006 Symptomatic 227 280,738 ++ +++ + R5X4R8
UCFL1007 Symptomatic 106 75,639 +++ ++ ++ R5X4R8
UCFL1008 Symptomatic 238 172,720 +++ − ++ R5R8
UCFL1009 Symptomatic 409 2,742,788 + ++ + R5X4R8
UCFL1010 Symptomatic 274 ND +++ ++ − R5X4
UCFL1011 Symptomatic 1428 1595 ++ +++ + R5X4R8
UCFL1013 Asymptomatic 446 1,876,150 ++ − ++ R5R8
UCFL1014 Symptomatic 305 67,508 ++ + − R5X4
UCFL1015 Symptomatic 259 120,345 +++ +++ +++ R5X4R8
UCFL1016 Asymptomatic 453 6521 +++ +++ +++ R5X4R8
UCFL1017 Asymptomatic 563 281,934 ++ − − R5
UCFL1018 Symptomatic 451 192,969 + + + R5X4R8
UCFL1019 Symptomatic 125 5765 − + + X4R8
UCFL1020 Symptomatic 118 164,230 ++ + ++ R5X4R8
UCFL1021 Asymptomatic 1076 b500 ++ ++ ++ R5X4R8
UCFL1022 Symptomatic 394 246,641 +++ ++ ++ R5X4R8
UCFL1023 Asymptomatic 349 b500 + + − R5X4
UCFL1024 Symptomatic 187 387,659 ++ + ++ R5X4R8
UCFL1025 Asymptomatic 578 b500 ++ − − R5
UCFL1026 Symptomatic 278 178,364 +++ + − R5X4
UCFL1027 Symptomatic 451 70,557 +++ +++ +++ R5X4R8
UCFL1028 Symptomatic 218 237,482 +++ + − R5X4
UCFL1029 Synptomatic 1455 b500 +++ + − R5X4
UCFL1030 Symptomatic 183 56,457 +++ − + R5R8
UCFL1031 Symptomatic 123 387,237 ++ ++ − R5X4
a Clinical stage according to CDC classiﬁcation (CDC, 1992); Asymptomatic = clinical
stage A; Symptomatic = clinical stage B or C.
b Number of T-CD4 lymphocytes/μl.
c Copies of viral RNA/ml; ND, not determined.
d Peak RT activity measured in culture supernatants during a 21 day-period after
virus inoculation. − peak RT activity b10 pg/ml; + peak RT activity between 10 and
100 pg/ml; ++ peak RT activity between 101 and 1000 pg/ml; +++ peak RT activity
N1000 pg/ml.
179M. Calado et al. / Virology 408 (2010) 174–1822005) suggesting that CCR8 may indeed prove to be a signiﬁcant
coreceptor for certain isolates of HIV-1 and HIV-2.
Our results demonstrate that CCR8 was effectively used by
seventeen out of 65 HIV-2 isolates tested (26.2%). The usage of
minor coreceptors, namely CCR8, in HIV-2 infection could be
somewhat predicted by the well-known promiscuous usage of
chemokine receptors that, in general, characterize HIV-2 strains
(Bron et al., 1997; Guillon et al., 1998; McKnight et al., 1998). More
surprisingly, however, was the frequency with which CCR8 was used
by HIV-1 isolates: 56.7% of the strains tested were able to infect CCR8-
expressing cells. This data raises once again the question of whether
alternate molecules, such as CCR8, can in vivo contribute to HIV
infection of natural target cells, at least under certain circumstances.
This is particularly important when anti-CCR5 antagonists are being
used in clinical practice and the coreceptor phenotype assays only
detect CCR5 vs. CXCR4 variants. If an even minor viral population
using CCR8 (or other coreceptors) is present in an infected patient, it
will not be detected, with potential implications in therapeutic
success and possibly also in the pathogenesis. However, it is
important to emphasize that the capacity of HIV primary isolates to
exploit coreceptors in indicator cell lines, such as GHOST–CD4+ cell
lines, does not provide an exact indication of coreceptor usage in vivo.
The levels of coreceptor expression in naturally occurring cells are, in
general, lower than those observed in genetically engineered cell lines
expressing CD4 and a chemokine receptor. Accordingly, the inferenceof in vivo coreceptor usage based on in vitro assay should be assumed
with caution. Nevertheless, the ﬁndings presented in this report,
together with previous data indicating that CCR8 can function
efﬁciently as coreceptor for diverse HIV-1 and HIV-2 isolates, either
in indicator cell lines or in primary cells (Cilliers et al., 2005; Horuk
et al., 1998; Jinno et al., 1998; Lee et al., 2000; Liu et al., 2000; Rucker
et al., 1997; Shimizu et al., 2009), highlight the potential relevance of
this molecule for viral pathogenesis.
It is widely recognized that during later stages of HIV-1 infection, a
signiﬁcant proportion of viral variants that constitute the quasispecies
within an infected individual, evolve in order to efﬁciently use CXCR4
(and probably other chemokine receptors) in addition to, or instead of,
CCR5-using variants, whichpredominate during early stages of infection
(Connor et al., 1997; Su et al., 1997). TheemergenceofX4variantsoccurs
in approximately half of the infected patients and is associated with
accelerated disease progression and increased CD4+ T-lymphocytes
depletion (Connor et al., 1997). Thesehigher rates of diseaseprogression
and CD4+ T-cell depletion have been related to several viral factors,
namely to an increase in replicative capacity and a more cytopathic
phenotype of X4 viruses to primary CD4+ lymphocytes (Fouchier et al.,
1996; Tersmette et al., 1989; van't Wout et al., 1998).
Our results reveal that the CXCR4 usage, either alone or together
with CCR5 and/or CCR8 (R5X4 or R5X4R8 biotype, respectively), was
more frequently observed in HIV-1 than in HIV-2 isolates (83.3% and
47.7%, respectively). Directly related to this is the ﬁnding that the non-
usage of CXCR4 and/or CCR8 (R5 biotype) is signiﬁcantly more
common in HIV-2 isolates than in HIV-1 (46.2% and 6.7%, respective-
ly). Even considering that in vitro isolation and propagation of HIV
isolates may either reﬂect the full diversity of viral quasispecies or,
instead, result in the selection of only a subset of HIV variants present
in the patient's PBMC (those with the most ﬁt phenotype under the in
vitro culture conditions), this data suggests that the acquisition of
CXCR4 usage could be more common in HIV-1 quasispecies and
preservation of R5 biotype more frequently observed in HIV-2 viral
population. Both features may be related with the slower disease
progression generally observed in HIV-2 infected patients compared
with HIV-1. Although tempting, this inference must also bear in mind
the existence of intrinsic differences between our HIV-2 and HIV-1
patient cohorts, even considering that they both show a similar
percentage of symptomatic patients, as well as a proportional number
of patients with low CD4+ T-cell counts.
Furthermore, we cannot exclude the possible contribution of other
coreceptors besides those included in this study (i.e. CCR5, CXCR4 and
CCR8). Nevertheless, the emergence and predominance of a CXCR4-
using viral population mostly observed in HIV-1 cohort, could be seen
as an additional contribution to an accelerated disease progression.
Speciﬁcally, the ability to infect naïve T-cells by X4 variants, which
could occur early in T-lymphocyte ontogeny, may contribute to the
described enhancement of T-cell depletion by X4 strains. Several
studies addressing thymocyte development, have demonstrated that
immature T-cell progenitor expresses high levels of CXCR4 (Berkowitz
et al., 1998; Kitchen and Zack, 1997; Taylor et al., 2001; L. Zhang et al.,
1998). As a result, infection of immature thymocytes by X4 strainsmay
disrupt thymopoiesis leading to an impairment of T-cell development
and to an accelerated T-cell depletion (Berkowitz et al., 1998; Kitchen
and Zack, 1997; Taylor et al., 2001). Furthermore, HIV-1 X4 variants
are associatedwithmassive induction of apoptosis in bystander CD4+
T-cells; while R5 stains appear to induce lower levels of programmed
cell death (Berndt et al., 1998; Biard-Piechaczyk et al., 1999;Herbein et
al., 1998; Jekle et al., 2003). Accordingly, the predominance of non-
CXCR4-using variants in HIV-2 individualsmay help to better preserve
CD4+ lymphocyte repertoire and immune system functionality than
in individuals infected with HIV-1, where a more frequent predom-
inance of CXCR4-using variants may be responsible for increased
apoptosis and limited T-cell regeneration, with direct impact in CD4+
T-cell homeostasis and immune function.
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In summary, our data conﬁrm that chemokine receptor CCR8 can
function as coreceptor for a signiﬁcant proportion of HIV-1 and HIV-2
primary isolates and may indeed be relevant as an alternative
coreceptor, at least under certain circumstances and/or particular
cell populations.We also conclude that the acquisition of CXCR4 usage
could be more common in HIV-1 quasispecies and the preservation of
R5 biotype more frequently observed in HIV-2 viral population. Both
features could be related with the slower disease progression
generally observed in HIV-2 infected patients compared with HIV-1.
Material and methods
Cells
Peripheral bloodmononuclear cells (PBMCs), fromHIV-uninfected
donors, homozygous for wild-type ccr5 gene [assessed as described
(Azevedo-Pereira et al., 2003)] were obtained from buffy-coats by
Ficoll–Hypaque density gradient centrifugation and stimulated with
phytohemagglutinin (3 μg/ml) for 3 days and maintained in RPMI-
1640 medium (Invitrogen, Paisley, UK) supplemented with 20 UI/ml
of human recombinant Interleukin 2 (IL-2), 15% (v/v) inactivated
Fetal Bovine Serum (Invitrogen, Paisley, UK), 50 μg/ml gentamicin and
2.5 μg/ml amphotericin B (Invitrogen, Paisley, UK). PBMCs used in all
experiments reported here were obtained from one single pool of
different buffy-coats to avoid inter-individual variations in HIV
infection susceptibility. Human osteosarcoma cell line GHOST expres-
sing different coreceptors and CD4 were maintained in Dulbecco's
modiﬁed Eagle's medium (Invitrogen, Paisley, UK) supplemented
with 10% (v/v) inactivated Fetal Bovine Serum, 50 μg/ml gentamicin,
2.5 μg/ml amphotericin B, 1 μg/ml puromycin, 100 μg/ml hygromycin
and 500 μg/ml G418 (Invitrogen, Paisley, UK).
HIV isolates
All primary HIV-1 and HIV-2 isolates were obtained from infected
patients' PBMC, by cocultivation with PHA-stimulated PBMC from
uninfected individuals. Viral replication was assessed by reverse
transcriptase activity in culture supernatants by an enzyme linked
immunosorbent assay (Lenti-RT kit, Caviditech, Uppsala, Sweden).
Viral stocks were established from low-passaged supernatants of
infected PBMC and stored at −80 °C until further use.
Infectivity assays
GHOST cell lines, expressing CD4 and chemokine receptors (CCR5,
CXCR4 and CCR8), were seeded into 24-well plates on the day prior to
infection, at a 1.5×105 cells/well. To assess chemokine usage, each
cell line was inoculated with 1 ng of reverse transcriptase activity of
each virus, in a ﬁnal volume of 100 μl, and incubated for 3 h, at 37 °C,
in the presence of 3 μg/ml of polybrene (Sigma-Aldrich, MO, USA).
Cells were then washed and cultured in appropriate culture medium
(500 μl/well). Viral replication was monitored by reverse transcrip-
tase (RT) activity, by an enzyme linked immunosorbent assay (Lenti-
RT kit, Caviditech, Uppsala, Sweden) or by the detection of Ag p24
(Vironostika HIV-1 Antigen; bioMérieux, Marcy l'Etoile, France) in
culture supernatants every 3 days, during 21 days. The infectivity
assays using GHOST cell lines also included the inoculation of GHOST–
CD4 parental cell line as a control.
Susceptibility to CCR5, CXCR4 and CCR8 inhibitors
The inhibitors TAK-779 (Baba et al., 1999) and AMD3100
(Donzella et al., 1998) speciﬁc for CCR5 and CXCR4, respectively,
were obtained through the National Institute of Health (NIH) AIDSResearch and Reference Reagent Program, Division of AIDS, NIAID,
NIH. The chemokine I-309, speciﬁc for CCR8 (Roos et al., 1997; Tiffany
et al., 1997), was purchased from R&D Systems (Minneapolis, MN).
Virus sensitivity to these different inhibitors was performed using
GHOST–CD4/CCR8 cell line or peripheral blood mononuclear cells
(PBMC) and was based on the inhibition of viral production as
described (Azevedo-Pereira et al., 2003). GHOST–CD4/CCR8 cells
were seeded at 1.5×105 cells per well in 24-well plates and allowed
to adhere overnight. Cells were incubated for 1 h at 37 °C with
blocking concentrations of each inhibitor: 100 ng/ml of I-309 (Horuk
et al., 1998), 100 nM of TAK-779 and 1.2 μM of AMD3100 (Bobardt et
al., 2007). Viruses were then added as described in infectivity assays
and incubated for 4 h in an inhibitor-containing medium. Cells were
washedwith PBS to remove unadsorbed viral particles and cultured in
an appropriate medium containing the desired concentration of each
inhibitor. Alternatively, these inhibition assays were also performed
using CD8-depleted PBMCs as target cells, which were obtained from
PBMCs after removal of CD8+ cells, using magnetic beads coated with
anti-CD8 antibody (Dynabeads, Dynal, Invitrogen, Paisley, UK),
according to the manufacturer's instructions.
Virus production was assessed by RT activity in culture super-
natants, 7 days after infection. Residual viral replication (percentage)
in the presence of an inhibitor was calculated as 100×(RTInhib /
RTcontrol), RTcontrol being the infection in the absence of inhibitors.Statistical analysis
Statistical analysis was performed using Epi info version 6.04 (CDC,
Atlanta, USA) and SPSS software version 10 (SPSS Inc, Chicago, USA).
The univariate analysis was tested using χ2 and 2-tailed Fisher's exact
test in case of small sample size. Statistical signiﬁcance was assumed
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